RxDoctor Payments Data

Bernardo Trujillo

Family · Riverview, FLNPI 1780132001

Payments from drug & device makers

$862in general payments, 2019–2025

Across 38 payments — averaging $22.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$286
  • Lilly USA, LLC$173
  • Novo Nordisk$150
  • AbbVie$88
  • Boehringer Ingelheim$61
  • GSK$48
  • plus $57 from 3 others

What the payments were for

  • Food & beverage$862100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$862 in reported general payments places this provider in the 65th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$3,776
Medicare patients
23
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$48,118
XareltoRivaroxaban15$22,081
FarxigaDapagliflozin Propanediol16$18,386
JardianceEmpagliflozin16$16,538
MounjaroTirzepatide15$16,182
EliquisApixaban16$13,083
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,909
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$5,571
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,414
Albuterol Sulfate HfaAlbuterol Sulfate77$1,733
Atorvastatin Calcium120$1,193
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic11$968
Gabapentin58$860
Omeprazole42$831
Losartan Potassium79$797

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$150$48,11836 claims
AstraZenecaFarxiga$13$18,38616 claims
Boehringer IngelheimJardiance$61$16,53816 claims
Lilly USA, LLCMounjaro$173$16,18215 claims
GSKTrelegy Ellipta$48$11,90918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 14,618 family providers in Florida.

Other family in Riverview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →